anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1\. Ensure DonorCare® Needle Guard (DCNG) is positioned on the tubing between the needle hub and Pinch Clamp. Engage Pinch Clamp. Ensure tethered cap is placed securely on the air vent.

2\. Using aseptic technique, insert needle into umbilical vein, disengage Pinch Clamp to collect cord blood, mixing frequently, according to standard procedures.

3\. Upon completion of collection, engage Pinch Clamp then withdraw needle from umbilical vein. Slide the DCNG midway over the needle hub. While holding the sides of DCNG near front, grasp tubing and pull smoothly, pulling needle into the DCNG until it locks into place. Confirm that needle is locked by listening for the second click as the needle is drawn into the DCNG. Ensure that tubing cannot be pulled through DCNG.

4\. Place the bag on a work surface. While holding the tubing above the bag, open the tethered cap on the air vent. Allow the blood to drain from the tubing into the bag.

5\. When the tubing has been drained, hold tubing vertical and seal tubing directly below the Y-piece with air vent.

6\. Detach and discard needle, DCNG, Pinch Clamp, Air Vent and tubing according to standard procedures.

7\. Determine amount of anticoagulated blood collected. If required, add sedimenting agent to CPD anticoagulated blood through Sample Port using a syringe according to standard procedures.

8\. Mix well. Take care to strip and mix any blood in tubing.

9\. Load bag into centrifuge cup. It is suggested that a means of support is used to prevent bag from collapsing and to reduce wrinkles.

10\. Centrifuge according to standard procedures to obtain mononuclear cell-rich plasma.
PURPOSE:To obtain the subject medicinal wheat yeast rich in active components of medicinal plants, mineral, etc., low in yeast odor, capable of readily administration and having a high drug efficacy by adding medicinal plants to a malt liquid, heating the resultant mixture, adding a yeast to the heat treated malt liquid and carrying out fermentative culture. CONSTITUTION:Medicinal plants (preferably Atemisial capillaris flos, Ervthraea centaurium Pers. and glycyrrhiza) are added to a malt liquid and heated. A yeast (preferably Saccharomyces cereviciae, Pichia stipitis, etc.) is added thereto and the resultant mixture is subjected to fermentative culture. The resultant yeast is mixed with the medicinal plants to obtain the objective yeast. The obtained yeast is formed, thus obtaining the objective medicinal wheat yeast drug.
INTRODUCTION: Burn neck contractures pose a great challenge for reconstructive surgeons. A paucity of literature exist regarding long-term outcomes based on different surgical management strategies. The aim of this study was to evaluate the long-term outcomes of the treatment of neck burn scar contractures and evaluate surgical strategies according to their long-term effectiveness and associated complications.
METHODS: A retrospective cohort study was conducted to review outcomes of neck contractures release after burn injury. All patients operated on between January 2009 and February 2023 at a single institution were included.
RESULTS: A total of 20 patients developed neck burn scar contracture and were included in this study. The mean age was 32.9 ± 20.3 years. The burn injuries were most commonly thermal (n = 19, 95%). All burn injuries were full-thickness burns, with an average neck defect size of 130.5 ± 106.0 cm2. Overall, 45 surgical scar release procedures were performed on the 20 patients who developed a neck contracture. Patients underwent 1.65 ± 1.04 surgeries on average to address neck contracture. Although 25% of patients only received 1 surgery to treat neck contracture, some patients underwent as many as 8 surgeries. Contracture recurrence (CR) was the most common complication and occurred in 28.9% of the cases. The mean percentage total body surface area did not significantly differ in CR patients (26.7% ± 14.9%) and no-CR patients (44.5% ± 30.2%). However, there was a significant difference (P = 0.01) in the average neck defect size between CR patients (198.5 ± 108.3 cm2) and no-CR patients (81.1 ± 75.1 cm2).
CONCLUSIONS: This study showed that risk factors for initial burn scar contractures may differ from those associated with CR, highlighting the importance of neck defect size as a predictor. The study also examines various surgical approaches, with Z-plasty showing promise for managing CR. However, the absence of data on neck range of motion is a limitation. This research underscores the complexity of managing CR and emphasizes the need for ongoing postoperative monitoring.
PURPOSE: An intravenous composition for arthritis treatment for animals except human is provided to enhance prevention and treatment effects of diseases related to aging by directly injecting active ingredients into blood stream. CONSTITUTION: An intravenous composition for arthritis treatment for animals except human contains wild ginseng extract. 0.1-10 wt% of the wild ginseng extract is included based on the total weight. The non-human animal is racehorse. The intravenous composition additionally includes red ginseng extract. The intravenous composition additionally includes one kind of extract selected from Chinese matrimony vine, Torilidis Fructus, schizandra, and wild field berry extract. The intravenous solution composition additionally includes extract of raw persimmon, persimmon, Chrysanthemum morifolium, Actinidia arguta, Citrus junos, Eucommia ulmoides, Cassiae Semen, jujube, Acanthopanacis Cortex Radicis or wild rose.
Patients will attend two sessions of one-to-one training with a physical therapist to learn the shoulder home exercise program. The sessions are 4 weeks apart. They will also review a handout on techniques to protect their shoulder during wheelchair propulsion and transfers.
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.

Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

Among the 418 patients who were treated with Unituxin in combination with GM-CSF, IL-2, and RA in Study 2, Study 3 and Study DIV-NB-201, 86 patients (20.6%) tested positive for anti-dinutuximab antibodies (ADA). Of the 86 ADA positive patients, 45 (52.3%) tested positive for neutralizing antibodies.

Among the 27 patients who were treated with Unituxin in combination with lenalidomide and isotretinoin in Study NANT 2011-04, 13 patients (48.1%) tested positive for ADA. Of the 13 ADA positive patients, 2 (15.4%) also tested positive for neutralizing antibodies.

The clearance of dinutuximab was 60% higher for the ADA positive patients than the ADA negative patients. The presence of ADA did not have a clinically significant effect on the incidence or severity of adverse reactions. There were insufficient number of patients with ADA to determine whether ADA alters the efficacy of Unituxin.
A synchronous clinical data collection, analysis and reporting system and method therefor are disclosed. The system collects and analyzes data from a patient, obtained via one or more medical devices. The medical devices include reference clinical devices installed at a medical setting that monitor vital signs and obtain signal data of the patient, and include one or more devices under test (DUT)s that obtain device-specific signal data. A clinical data recorder is configured to use signal data from one of the clinical devices as a reference signal to synchronize the signal data from each clinical device into clinical datasets. The reference signal is also used by the DUTs to synchronize the signal data from each of the DUTs into DUT datasets. Operators of the DUTs and an administrator of the system can access anonymized versions of the clinical datasets and/or the DUT datasets both during and after a medical session.
Arthroplasty of the knee will be performed within two weeks after the fracture. Medial parapatellar approach will be used. The minimal possible constraint of the prosthesis (cruciate retaining, posterior cruciate sacrificing or semi-constrained) will be used. A possible insufficient bone stock may be rebuilt with augments. Hinged prosthesis will be used only if stability of the medial collateral ligament is insufficient. A cemented or uncemented tibial stem extender (minimum length 50mm) will be used in all cases. Additional osteosynthesis will be used when necessary. Postoperatively, the patients will be allowed full weight bearing as tolerated.
Abnormalities of nicotinic acetylcholine system in schizophrenia are implied by the high prevalence of cigarette smoking. Because animal and human studies have shown that nicotinic acetylcholine receptors (nAChRs) play an important role in cognitive function, cognitive deficits in schizophrenia also suggest abnormalities in these receptors. Postmortem studies showed abnormalities in high affinity nAChRs in these patients but the direction of the abnormalities (increase or decrease) were not consistent probably because it is difficult to control the effects of cigarette smoking and neuroleptics in such studies. In vivo imaging studies are necessary to study relationship between nAChRs and psychiatric symptoms including cognitive impairments.

We plan to use a new single photon emission computed tomography (SPECT) tracer, \[(123)I\]5-I-A-85380, which appears suitable for imaging the high affinity Alpha 4 Beta 2 subtype of nAChRs. We plan to compare four groups, 1) schizophrenia smokers, 2) schizophrenia non-smokers, 3) healthy smokers, and 4) healthy non-smokers. All patients will be on stable doses of olanzapine or risperidone. In addition to comparing \[(123)I\]5-I-A-85380 binding among these groups, relationship will be studied between psychiatric symptoms or cognitive dysfunction and the SPECT measurement of the receptors. Further, to study the reliability of the SPECT measurement, a test retest study will be preformed in healthy subjects with a wide range. The proposed study will explore the roles of nAChRs in the psychiatric symptoms, particularly the cognitive deficits in schizophrenia, which is the central impairment of this disorder. New findings in this research will lead to enhanced treatment of the cognitive deficits.
The subject has a 50/50 chance of receiving either cohort. After the subject is randomized to receive either steroid given IV or with the nerve block, the subject is anesthetized and the subject will receive either an IV injection of 5 cc steroids or placebo, and 20 cc local anesthetic plus placebo or steroid in the nerve block, the block will be placed under ultrasound to insure proper placement of block, the dose of steroid is based on weight, 0.1 - 0.15 mg/kg. The investigator will record the time of block and IV injection. The subjects will be called by the study PI after 24 hours to determine the time of duration and again at 48 hours if needed. This is a randomized, double blind study, neither the subject or the anesthesiologist giving the injection will know what is being given. The medications will be prepared and dispensed by the Research pharmacist, a randomization chart will be obtained by the research pharmacist.
BACKGROUND: Preeclampsia, a pregnancy-specific condition associated with new-onset hypertension after 20-weeks gestation, is a leading cause of maternal and neonatal morbidity and mortality. Predictive tools to understand which individuals are most at risk are needed.
METHODS: We identified a cohort of N=1125 pregnant individuals who delivered between May 2015 and May 2022 at Mass General Brigham Hospitals with available electronic health record data and linked genetic data. Using clinical electronic health record data and systolic blood pressure polygenic risk scores derived from a large genome-wide association study, we developed machine learning (XGBoost) and logistic regression models to predict preeclampsia risk.
RESULTS: Pregnant individuals with a systolic blood pressure polygenic risk score in the top quartile had higher blood pressures throughout pregnancy compared with patients within the lowest quartile systolic blood pressure polygenic risk score. In the first trimester, the most predictive model was XGBoost, with an area under the curve of 0.74. In late pregnancy, with data obtained up to the delivery admission, the best-performing model was XGBoost using clinical variables, which achieved an area under the curve of 0.91. Adding the systolic blood pressure polygenic risk score to the models did not improve the performance significantly based on De Long test comparing the area under the curve of models with and without the polygenic score.
CONCLUSIONS: Integrating clinical factors into predictive models can inform personalized preeclampsia risk and achieve higher predictive power than the current practice. In the future, personalized tools can be implemented to identify high-risk patients for preventative therapies and timely intervention to improve adverse maternal and neonatal outcomes.
REDCHiP uses 10- video-based telemedicine sessions to deliver T1D education, behavioral parent training, and problem-solving to enhance parents' knowledge and skills. Sessions last about 45-60 minutes each.
A process is described for producing surrogate antibody molecules that mimic the structure, stability, and binding characteristics of a natural antibody. Surrogate antibody structure, composition of surrogate antibody libraries, methods of surrogate antibody preparation, and surrogate antibody applications are disclosed. Also disclosed are methods of surrogate antibody structural stabilization and resistance to nucleases. The surrogate antibodies comprise a specificity strand and a stabilization strand. The specificity strand comprises a nucleic acid sequence having a specificity region flanked by a first constant region and a second constant region. The stabilization strand comprises a first stabilization region and a second stabilization region that interacts with the second constant region. They can be used as an effective replacement for natural antibody molecules for testing therapeutic agents and research purposes.
CETA is a modular, multi-problem, flexible psychotherapy approach that trains a lay provider in nine evidence-based cognitive behavioral therapy (CBT) elements so the provider can treat a variety of common problems, including violence, substance use, depression, anxiety, risky behaviors (sexual, non-adherence), and other trauma-related symptoms. Patients randomized to CETA will meet weekly with a lay provider or community health worker member of the study staff for about an hour once each week, approximately 6-12 times depending on presentation and symptom level. This treatment arm will include Short Message Service (SMS) text reminders of their HIV care appointments, similar to the active control group. As of October 12, 2022 participants can elect to have CETA delivered by telephone.
### Pregnancy Category B

Cefditoren pivoxil was not teratogenic up to the highest doses tested in rats and rabbits. In rats, this dose was 1000 mg/kg/day, which is approximately 24 times a human dose of 200 mg BID based on mg/m2/day. In rabbits, the highest dose tested was 90 mg/kg/day, which is approximately four times a human dose of 200 mg BID based on mg/m2/day. This dose produced severe maternal toxicity and resulted in fetal toxicity and abortions.

In a postnatal development study in rats, cefditoren pivoxil produced no adverse effects on postnatal survival, physical and behavioral development, learning abilities, and reproductive capability at sexual maturity when tested at doses of up to 750 mg/kg/day, the highest dose tested. This is approximately 18 times a human dose of 200 mg BID based on mg/m2/day. 

There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
No application will be made to the mothers in the control group after the pre-test application. After 2 months, the final test application will be made. After the last test, the mothers in the control group will be given a training and a booklet prepared to prevent shaken baby syndrome.
INTRODUCTION: Two-stage exchange (TSE) is the gold standard for the treatment of chronic periprosthetic joint infection (PJI) after total joint arthroplasty of the hip and knee in the United States. Failure of treatment can have devastating consequences for the patient, including poor functional outcomes, multiple further surgeries, and increased mortality. Several factors associated with infection recurrence have previously been identified in the literature. The purpose of this study was to evaluate whether the use of a dual surgical setup was associated with reduced risk of recurrence after TSE for PJI.
METHODS: A retrospective study was conducted between January 2000 and December 2021 to isolate patients who underwent TSE after total joint arthroplasty of the hip and knee. Failure was defined as infection recurrence requiring surgical intervention. Demographic factors (age, sex, body mass index, smoking status, American Society of Anesthesiologists status), preoperative comorbidities (hypertension, cardiac disease, diabetes status, depression diagnosis, pulmonary disease), operating surgeon, single versus dual setup, hospital setting, use of long-term antibiotics postoperatively after TSE, aspiration data, and infecting organism were compared between cohorts using multivariate regression analysis.
RESULTS: A total of 134 patients were identified who underwent TSE after diagnosis of PJI. The mean follow-up was 67.84 (range, 13 to 236) months. Dual setup (odds ratio, 0.13; confidence interval, 0.02 to 0.52; P = 0.0122) was found to be an independent predictive variable associated with a lower risk of infection recurrence.
CONCLUSION: Utilization of a dual surgical setup is a low-cost modifiable risk factor associated with a lower risk of recurrence of after TSE of the hip and knee for PJI.
Thienopyridine compounds of Formula (I) and pharmaceutically acceptable salts thereof are provided. In these compounds, one of X, Xand Xis S, and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. A pharmaceutical composition for treating cancer comprising a compound and a pharmaceutically acceptable carrier or diluent is also provided. Provided is the use of a compound or a pharmaceutically acceptable salt thereof, as well as combinations thereof with an anti-PD-1 antibody for treating cancer. A method of treating cancer in a subject is also provided.
A solution for urushiol induced contact dermatitis is provided for in a topical solution. According to the invention, a method is provided for applying a composition of substances to the affected area, working the composition into the affected area, and removing the composition from the affected area. The composition comprises at least one ethoxylate in combination with a supporting agent. It is believed that this combination binds to the available urushiol receptors rendering it inactive. The affinity of the receptors for the ethoxylates also appears to cause a release of the urushiol from its epidermal bonds for bonding to the composition. An inert scrubbing agent, such as polyethylene beads, can also be included to assist in the release of the urushiol. Acetylated lanolin alcohol, EDTA, a foam stabilizer, and water can also be added to the composition without effecting performance.
Participants in the sleep hygiene arm will receive a 1 hr class directing them to the importance of following a list of up to 15 points (tips) for getting to sleep. These points include: limiting alcohol and caffeine intake before bed, using the bed only for sleeping, and having regular bedtimes. Once the instructor has gone over this list and has described in detail each of the 15 points, the class will have an opportunity to ask questions. The participant will be encouraged to learn and practice the objectives of the sleep hygiene class on a daily basis.
The embodiment of the application relates to the technical field of artificial intelligence, and discloses a recipe recommendation method, electronic equipment and a storage medium. Based on attribute information and input information of each recipe in the recall recipe list, a trained classification model is adopted to calculate the selection probability of each recipe so as to obtain an inference recipe list. And determining a recommended recipe list according to the recall recipe list and the reasoning recipe list. In this embodiment, the recalled recipe list is beneficial to the user's health. The list of inference recipes reflects the probability of user selection, i.e. preference bias. Therefore, the recommended recipe list can give consideration to health and personalized preference of the user, and is more reasonable.
Living WELL is a randomized clinical trial examining two different programs for helping ovarian cancer survivors cope and improve the quality of their lives following treatment. The programs include techniques and information to enhance both mental and physical well-being. The study is conducted through an internet video conferencing platform and is open to survivors in all parts of the US. The purpose of this study is to examine the effects of various factors such as emotions, stress management and coping techniques, and health information on quality of life, stress levels, depression, fatigue, and distress in ovarian cancer survivors. Participants are randomized into either a Mindful Living group (targeting stress management skills - e.g., relaxation, coping) or a Healthy Lifestyles group (targeting health promotion strategies - e.g, nutrition, sleep, exercise). Participation in this study includes taking part in an introductory online meeting, 10 consecutive weekly online sessions, and follow-up meetings at approximately 4.5 and 9 months following randomization. Each session will be 1.5-2 hours. Participants will complete surveys online prior to beginning the program, within a week after the 10-week program is completed, and at 6 months and 12 months later.
The study is a single-dose, randomized, cross-over study. The investigational products will be given as single doses at separate visits. The product administrations comprise 30 minutes of chewing. Periods without Nicotine Replacement Therapy (NRT), lasting for at least 36 hours, will separate treatment visits. Before and after the start of product administration at each treatment visit, blood will be sampled for pharmacokinetic analyses, pre-dose, and during 8 hours after start of product administration. Used gums will be collected and analyzed to determine the amount of remaining nicotine. Subjects will also be monitored to capture any adverse events that may occur. Treatment labels will be concealed from subjects, study personnel, monitor, and analysts.
Patients undergoing cancer therapy for the last 3-4 years with signs of heart failure and/or life-threatening arrhythmias. Administered interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.